Thoughts on the “Doctoral Glut Dilemma” Webinar

As I wrote last Thursday, ACS Webinars featured an hour-long discussion on the perceived overabundance of PhD-level chemists and potential solutions to employment challenges. The site should have the entire discussion archived within a week. I participated in the session and ended up posting my thoughts at the new Forbes.com home of my other blog, Take As Directed. I’m hoping to get comments from a wider group of readers over...

Read More

Today: Solutions to the “Doctoral Glut Dilemma”

Don’t say ACS have their heads in the sand. A webinar this afternoon will face head-on the reality of training to be a doctoral-level chemist in today’s job market.  Is higher education producing more doctoral scientists than the market can absorb? With the attendance rates at graduate schools increasing, has the private sector’s growth been able to keep up and will there be enough options for tomorrow’s PhDs?   Join our...

Read More

The Colorado shooting suspect: how “smart?”

Apologies in advance to any readers who might be put off by my writing about the science aspects of the Colorado movie theater tragedy. I was a faculty member at the University of Colorado in Denver from 1992 to 2001 and was in the area during the Columbine High School shooting rampage. I also still have some friends out there and feel a personal connection to the place and people who helped launch my independent research career....

Read More

WaPo: Not enough jobs for science PhDs

Tomorrow’s frontpage of The Washington Post will run an article by Brian Vastag (Twitter, WaPo bio) on the employment challenges facing science PhDs. The difficulties are no secret to our readers – whether you are a freshly-minted PhD or a 50-something subjected to downsizing – but I believe that this is the highest profile treatment of the subject in the US print media. The article even cites the closure of the...

Read More

NIDA seeks SBIR/STTR apps on Spice, bath salts

C&EN senior business editor Melody Bomgardner dropped me a note yesterday about a new request for applications from NIH’s National Institute on Drug Abuse (NIDA) for small business grants. Read the text below but here’s what I find interesting as a pharmacologist who plays well with chemists: the call for applications is not for analytical methods for designer drugs. Rather the announcement solicits novel methods for...

Read More